Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur- 603203, Tamil Nadu, India.
Curr Comput Aided Drug Des. 2021;17(1):144-159. doi: 10.2174/1573409916666200320162948.
A better understanding of the biopharmaceutical and physicochemical properties of drugs and the pharmaco-technical factors would be of great help for developing pharmaceutical products. But, it is extremely difficult to study the effect of each variable and interaction among them through the conventional approach.
To screen the most influential factors affecting the particle size (PS) of lipid nanoparticle (LNPs) (solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC)) for poorly watersoluble BCS class-II drug like tamoxifen (TMX) to improve its oral bioavailability and to reduce its toxicity to tolerable limits using Taguchi (L (2)) orthogonal array design by applying computer optimization technique.
The size of all LNPs formulations prepared as per the experimental design varied between 172 nm and 3880 μm, polydispersity index between 0.033 and 1.00, encapsulation efficiency between 70.8% and 75.7%, and drug loading between 5.84% and 9.68%. The study showed spherical and non-spherical as well as aggregated and non-aggregated LNPs. Besides, it showed no interaction and amorphous form of the drug in LNPs formulation. The Blank NLCs exhibited no cytotoxicity on MCF-7 cells as compared to TMX solution, SLNs (F5) and NLCs (F12) suggest that the cause of cell death is primarily from the effect of TMX present in NLCs.
The screening study clearly showed the importance of different individual factors significant effect for the LNPs formulation development and its overall performance in an in-vitro study with minimum experimentation thus saving considerable time, efforts, and resources for further in-depth study.
更好地了解药物的生物制药和物理化学性质以及药剂学因素将有助于开发药物产品。但是,通过传统方法研究每个变量的影响及其相互作用非常困难。
使用 Taguchi(L(2))正交数组设计,通过应用计算机优化技术,筛选出影响疏水性 BCS 类 II 药物如他莫昔芬(TMX)的脂质纳米粒(LNPs)(固体脂质纳米粒(SLN)和纳米结构脂质载体(NLC))粒径(PS)的最具影响力的因素,以提高其口服生物利用度并将其毒性降低到可耐受的限度。
根据实验设计制备的所有 LNPs 制剂的粒径在 172nm 至 3880μm 之间,多分散指数在 0.033 至 1.00 之间,包封效率在 70.8%至 75.7%之间,载药量在 5.84%至 9.68%之间。研究表明 LNPs 制剂具有球形和非球形以及聚集和非聚集两种形态。此外,还表明药物在 LNPs 制剂中呈无相互作用和非晶态。与 TMX 溶液、SLNs(F5)和 NLCs(F12)相比,空白 NLCs 对 MCF-7 细胞没有细胞毒性,这表明细胞死亡的原因主要是由于 NLCs 中存在的 TMX。
筛选研究清楚地表明了不同个体因素对 LNPs 制剂开发及其在体外研究中的整体性能的重要性,与进一步深入研究相比,该研究通过最小化实验,节省了大量的时间、精力和资源。